Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Missed opportunities of inclusion in a cohort of HIV-infected children to initiate antiretroviral treatment before the age of two in West Africa, 2011 to 2013.

Dahourou DL, Amorissani-Folquet M, Coulibaly M, Avit-Edi D, Meda N, Timite-Konan M, Arendt V, Ye D, Amani-Bosse C, Salamon R, Lepage P, Leroy V; Monod Anrs 12206 Study Group.

J Int AIDS Soc. 2016 Mar 23;19(1):20601. doi: 10.7448/IAS.19.1.20601. eCollection 2016.

2.

Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.

Giandhari J, Basson AE, Sutherland K, Parry CM, Cane PA, Coovadia A, Kuhn L, Hunt G, Morris L.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2248-56. doi: 10.1128/AAC.02682-15. Print 2016 Apr.

PMID:
26833162
3.

Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children.

Rabie H, Frigati L, Hesseling AC, Garcia-Prats AJ.

J Int AIDS Soc. 2015 Dec 2;18(Suppl 6):20236. doi: 10.7448/IAS.18.7.20236. eCollection 2015. Review.

4.

Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.

Coovadia A, Abrams EJ, Strehlau R, Shiau S, Pinillos F, Martens L, Patel F, Hunt G, Tsai WY, Kuhn L.

JAMA. 2015 Nov 3;314(17):1808-17. doi: 10.1001/jama.2015.13631.

5.

Growth reconstitution following antiretroviral therapy and nutritional supplementation: systematic review and meta-analysis.

McGrath CJ, Diener L, Richardson BA, Peacock-Chambers E, John-Stewart GC.

AIDS. 2015 Sep 24;29(15):2009-23. doi: 10.1097/QAD.0000000000000783. Review.

PMID:
26355573
6.

Factors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South Africa.

Rossouw TM, Feucht UD, Melikian G, van Dyk G, Thomas W, du Plessis NM, Avenant T.

PLoS One. 2015 Jul 21;10(7):e0133452. doi: 10.1371/journal.pone.0133452. eCollection 2015.

7.

Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.

Giandhari J, Basson AE, Coovadia A, Kuhn L, Abrams EJ, Strehlau R, Morris L, Hunt GM.

AIDS Res Hum Retroviruses. 2015 Aug;31(8):776-82. doi: 10.1089/AID.2014.0349. Epub 2015 Jun 4.

8.

The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.

Soeters HM, Sawry S, Moultrie H, Rie AV.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):136-44. doi: 10.1097/QAI.0000000000000284.

9.

Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.

Shiau S, Kuhn L, Strehlau R, Martens L, McIlleron H, Meredith S, Wiesner L, Coovadia A, Abrams EJ, Arpadi SM.

BMC Pediatr. 2014 Feb 12;14:39. doi: 10.1186/1471-2431-14-39.

10.

Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen.

Moholisa RR, Schomaker M, Kuhn L, Meredith S, Wiesner L, Coovadia A, Strehlau R, Martens L, Abrams EJ, Maartens G, McIlleron H.

Antivir Ther. 2014;19(4):399-406. doi: 10.3851/IMP2749. Epub 2014 Feb 12.

11.

Mortality and long-term virologic outcomes in children and infants treated with lopinavir/ritonavir.

Estripeaut D, Mosser J, Doherty M, Acosta W, Shah H, CastaƱo E, Luciani K, Pascale JM, Bollinger RC, Page KR.

Pediatr Infect Dis J. 2013 Dec;32(12):e466-72. doi: 10.1097/INF.0b013e3182a09276.

12.

Adherence and viral suppression among infants and young children initiating protease inhibitor-based antiretroviral therapy.

Teasdale CA, Abrams EJ, Coovadia A, Strehlau R, Martens L, Kuhn L.

Pediatr Infect Dis J. 2013 May;32(5):489-94. doi: 10.1097/INF.0b013e31827e84ba.

13.

Effect of antiretroviral therapy on clinical and immunologic disease progression in HIV positive children: One-year follow-up study.

Patel A, Trivedi SS, Chudasama RK, Patel PK.

J Family Community Med. 2012 Sep;19(3):178-83. doi: 10.4103/2230-8229.102318.

14.

PEPFAR scale-up of pediatric HIV services: innovations, achievements, and challenges.

Abrams EJ, Simonds RJ, Modi S, Rivadeneira E, Vaz P, Kankasa C, Tindyebwa D, Phelps BR, Bowsky S, Teasdale CA, Koumans E, Ruff AJ.

J Acquir Immune Defic Syndr. 2012 Aug 15;60 Suppl 3:S105-12. doi: 10.1097/QAI.0b013e31825cf4f5. Review.

15.

Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.

Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, Meyers T, Sherman G, Hunt G, Persaud D, Morris L, Tsai WY, Abrams EJ.

Lancet Infect Dis. 2012 Jul;12(7):521-30. doi: 10.1016/S1473-3099(12)70051-8. Epub 2012 Mar 16.

16.

Unresolved antiretroviral treatment management issues in HIV-infected children.

Heidari S, Mofenson LM, Hobbs CV, Cotton MF, Marlink R, Katabira E.

J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):161-9. doi: 10.1097/QAI.0b013e3182427029. Review.

17.

Tuberculosis in human immunodeficiency virus infected Ugandan children starting on antiretroviral therapy.

Bakeera-Kitaka S, Conesa-Botella A, Dhabangi A, Maganda A, Kekitiinwa A, Colebunders R, Boulware DR.

Int J Tuberc Lung Dis. 2011 Aug;15(8):1082-6. doi: 10.5588/ijtld.10.0538.

18.

HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, Kuhn L.

AIDS. 2011 Jul 31;25(12):1461-9. doi: 10.1097/QAD.0b013e3283492180.

19.

Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.

Frohoff C, Moodley M, Fairlie L, Coovadia A, Moultrie H, Kuhn L, Meyers T.

PLoS One. 2011 Feb 23;6(2):e17273. doi: 10.1371/journal.pone.0017273.

20.

Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.

Taylor BS, Hunt G, Abrams EJ, Coovadia A, Meyers T, Sherman G, Strehlau R, Morris L, Kuhn L.

AIDS Res Hum Retroviruses. 2011 Sep;27(9):945-56. doi: 10.1089/AID.2010.0205. Epub 2011 Mar 23.

Items per page

Supplemental Content

Write to the Help Desk